Status:
COMPLETED
Spironolactone in Diabetic Nephropathy
Lead Sponsor:
Steno Diabetes Center Copenhagen
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuri...
Eligibility Criteria
Inclusion
- Diabetes Mellitus
- Diabetic Nephropathy
- Glomerular filtration rate \> 30 ml/min/1.73 m2
- Blood pressure \> 130/80 mm Hg
Exclusion
- Child bearing potential
- Plasma-potassium \>4.5 mmol/l
- Breastfeeding
- Abuse of alcohol or drugs
- Non-diabetic kidney disease
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00317954
Start Date
September 1 2003
End Date
July 1 2005
Last Update
April 25 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Steno Diabetes Center
Gentofte Municipality, Denmark, 2820